APA citiranje

Liu, W., Yin, Y., Wang, J., Shi, B., Zhang, L., Qian, D., . . . Zhang, B. (2016). Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC. Oncotarget.

Citação norma Chicago

Liu, Weiran, et al. "Kras Mutations Increase Telomerase Activity and Targeting Telomerase Is a Promising Therapeutic Strategy for Kras-mutant NSCLC." Oncotarget 2016.

MLA citiranje

Liu, Weiran, et al. "Kras Mutations Increase Telomerase Activity and Targeting Telomerase Is a Promising Therapeutic Strategy for Kras-mutant NSCLC." Oncotarget 2016.